Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Prophylactic oseltamivir treatment for prevention of donor–recipient influenza A H1N1 virus transmission does not compromise stem cell mobilization or engraftment

Bone Marrow Transplantation volume 46, pages 312–313 (2011)Cite this article

Subjects

In April 2009, the novel influenza A (H1N1) 2009 virus had its primary outbreak in Mexico and spread throughout the world within weeks.1 The severity of the illness seems comparable to seasonal influenza, even though the virus appears to cause higher rates of lower respiratory tract infections leading to acute respiratory distress syndrome and mechanical ventilation.2 Immunocompromised patients are at especially high risk for complications and mortality from this infection.3

We report on a 45-year-old Caucasian woman suffering from therapy-related myelodysplastic syndrome acquired 3 years after primary treatment for cytogenetically high-risk chronic B-cell lymphatic leukemia consolidated by auto-SCT. The patient was admitted to our center for allo-SCT from her matched sibling donor. Reduced-intensity conditioning therapy consisted of fludarabine 30 mg/m2 once daily i.v. for 5 consecutive days (day −6 to −2) and melphalan 150 mg/m2 once daily i.v. on day −2 commenced during induction chemotherapy-induced aplasia.4 Except for a short period of streptococcal bacteremia-induced fever, which resolved within 2 days after specific antibiotic therapy, induction and conditioning therapy was well tolerated.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Zarocostas J . World Health Organization declares A (H1N1) influenza pandemic. BMJ 2009; 338: b2425.

    Article  Google Scholar 

  2. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009; 460: 1021–1025.

    Article  CAS  Google Scholar 

  3. Lapinsky SE . H1N1 novel influenza A in pregnant and immunocompromised patients. Crit Care Med 2010; 38 (4 Suppl): e52–57.

    Article  Google Scholar 

  4. Platzbecker U, Thiede C, Fussel M, Geissler G, Illmer T, Mohr B et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia 2006; 20: 707–714.

    Article  CAS  Google Scholar 

  5. Ljungman P . Respiratory virus infections in stem cell transplant patients: the European experience. Biol Blood Marrow Transplant 2001; 7 (Suppl): S5–S7.

    Article  Google Scholar 

  6. Likos AM, Kelvin DJ, Cameron CM, Rowe T, Kuehnert MJ, Norris PJ et al. Influenza viremia and the potential for blood-borne transmission. Transfusion 2007; 47: 1080–1088.

    Article  Google Scholar 

  7. Nichols WG, Guthrie KA, Corey L, Boeckh M . Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004; 39: 1300–1306.

    Article  Google Scholar 

  8. Uyeki T . Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1). N Engl J Med 2009; 361: e110.

    Article  Google Scholar 

  9. Raisch DW, Straight TM, Holodniy M . Thrombocytopenia from combination treatment with oseltamivir and probenecid: case report, MedWatch data summary, and review of the literature. Pharmacotherapy 2009; 29: 988–992.

    Article  Google Scholar 

  10. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175–181.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Internal Medicine, Medical University of Graz, Styria, Austria

    A Rohn, W Linkesch & P Neumeister

  2. Molecular Diagnostics Laboratory, Center for Applied Biomedicine, Medical University of Graz, Styria, Austria

    H H Kessler

  3. Division of Pulmonology, Department of Internal Medicine, Section of Infectious Diseases, Medical University of Graz, Styria, Austria

    T Valentin

Authors
  1. A Rohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H H Kessler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Valentin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W Linkesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Neumeister
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Rohn.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rohn, A., Kessler, H., Valentin, T. et al. Prophylactic oseltamivir treatment for prevention of donor–recipient influenza A H1N1 virus transmission does not compromise stem cell mobilization or engraftment. Bone Marrow Transplant 46, 312–313 (2011). https://doi.org/10.1038/bmt.2010.97

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.97

Search

Advanced search

Quick links